Bard PowerPort claims: who can file and what to do in Illinois

MDL 3081 (In re: Bard PowerPort) is before Chief Judge David G. Campbell in the District of Arizona. Illinois cases, primarily from the Northern District of Illinois (Chicago), are transferred to Phoenix for centralized pretrial proceedings. Chicago’s large teaching hospital and oncology center population contributes a significant volume of cases to MDL 3081, with multiple major cancer centers reporting high PowerPort implantation rates.

Illinois applies a 2-year statute of limitations for personal injury and product liability claims under 735 ILCS 5/13-202. Illinois’s discovery rule tolls the limitations period until the plaintiff knew or reasonably should have known of the injury and its connection to the PowerPort device. Illinois courts have applied the discovery rule broadly in latent medical device injury cases, which is critical where catheter fracture is asymptomatic until fragment migration causes acute cardiac or pulmonary injury.

Illinois’s oncology network includes the Robert H. Lurie Comprehensive Cancer Center at Northwestern (Chicago), University of Chicago Medicine Comprehensive Cancer Center, Rush University Medical Center’s cancer program, and NorthShore University Health System. Chicago’s dense hospital market and large chemotherapy patient volume result in high PowerPort utilization rates, and Illinois patients are well-represented among MDL 3081 claimants.

The primary federal venue for Illinois PowerPort plaintiffs is the N.D. Ill. (Eastern Division, Chicago), which transfers cases to MDL 3081. BD (Becton, Dickinson) operates Midwest regional medical device sales operations from its Illinois presence and supplies Bard PowerPort devices through major Illinois GPO contracts. BD’s Illinois contacts support specific personal jurisdiction, and the Northern District is one of the highest-volume feeder courts to MDL 3081.